1 in 3 Adults Have THIS Liver Disease and Don't Know It (How to Reverse It)

Published: March 22, 2026  ·  Last updated: April 28, 2026

If you've never heard of MASLD, you're not alone — the name was officially adopted in 2023, replacing the older term NAFLD (non-alcoholic fatty liver disease). The renaming wasn't cosmetic. It was an acknowledgment that defining a disease by what it isn't ('non-alcoholic') had distracted from what it actually is — a metabolic condition driven by insulin resistance, central obesity, type 2 diabetes, and high triglycerides.

Whatever you call it, the prevalence is enormous. About a third of US adults have fatty liver disease, most don't know, and the early stages are usually asymptomatic. The condition can progress slowly over years to liver fibrosis, cirrhosis, and in some cases liver cancer — but the early stages are often reversible with the right interventions. The window to catch and reverse it is wide. The opportunity is in knowing it exists and that it likely affects you.

Why the Name Changed — and What It Tells You

Per AASLD's announcement of the new MASLD nomenclature, the change was made because the older 'non-alcoholic fatty liver disease' framing was diagnostic by exclusion — it told you what the disease wasn't, not what it was. As research advanced, it became clear that the actual driver of fat accumulation in the liver in most cases is metabolic dysfunction: insulin resistance, central adiposity, dyslipidemia, type 2 diabetes, and hypertension.

MASLD requires both fat in the liver (steatosis) AND at least one cardiometabolic risk factor (overweight or obesity, type 2 diabetes, high blood pressure, high triglycerides, or low HDL cholesterol). The new definition explicitly links liver disease to the metabolic syndrome cluster that drives so much chronic disease in adults.

There's also a related entity called MetALD (metabolic and alcohol-related liver disease) for adults with both metabolic dysfunction and significant alcohol intake. The cleaner classification helps clinicians and patients understand which interventions matter most for a given case.

How Common It Actually Is

Per PMC's review of MASLD epidemiology, the global prevalence has been estimated at roughly 30 percent of adults — and is rising in parallel with the obesity and type 2 diabetes epidemics. In the US, prevalence estimates range from 25 to 40 percent depending on the population studied and how it's measured.

The condition is particularly common in adults with type 2 diabetes (rates of 50 to 75 percent), with obesity (rates of 50 to 75 percent), and with metabolic syndrome features. Even adults with only moderate weight elevation, mild glucose intolerance, and elevated triglycerides have rates well above population baseline.

Despite the high prevalence, most people with MASLD have never been told they have it. The disease is often discovered incidentally — on an ultrasound or CT scan done for another reason, or when liver enzymes (ALT, AST) come back mildly elevated on a routine panel. Mildly elevated liver enzymes in an adult with metabolic syndrome features should specifically trigger a workup for MASLD.

What Progression Actually Looks Like

MASLD has a wide range of trajectories. Some adults have stable hepatic steatosis (fat in the liver) for decades without significant inflammation or fibrosis. Others progress through metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) — where the fat triggers inflammation that gradually damages liver tissue.

Per PMC's discussion of NAFLD-to-MASLD diagnostic implications, the highest-risk progression involves MASH that develops liver fibrosis. Fibrosis is the scarring that, over years, can become cirrhosis. The good news is that early-stage steatosis (fat without significant inflammation or fibrosis) is often reversible with sustained metabolic interventions. The bad news is that once fibrosis is established, reversal becomes harder, and once cirrhosis is established, the liver damage is generally permanent.

Risk of progression is higher in adults with type 2 diabetes, central obesity, persistently elevated liver enzymes, and significant alcohol intake on top of metabolic risk. Risk is lower in adults whose primary risk factor is overweight without diabetes or hypertension.

What Actually Reverses It

The most effective intervention for early MASLD is weight loss — specifically, sustained loss of 7 to 10 percent of body weight. At 5 to 7 percent loss, liver fat content drops measurably. At 10 percent and higher, MASH (the inflamed form) often improves and early fibrosis can stabilize or partially reverse. The mechanism is improved insulin sensitivity, reduced free fatty acid delivery to the liver, and reduced systemic inflammation.

Diet patterns with the strongest evidence: Mediterranean-style eating (emphasis on vegetables, whole grains, legumes, fish, olive oil; reduction in refined carbohydrates and added sugars), reduced or eliminated sugar-sweetened beverages, and reduced ultra-processed food intake. The specific reduction of fructose-sweetened drinks (sodas, juices) appears particularly impactful — fructose is preferentially metabolized in the liver and is a strong driver of hepatic fat accumulation.

Exercise produces additional liver benefits independent of weight loss — both aerobic and resistance training reduce hepatic fat content. Alcohol reduction or elimination is high-leverage in adults with MetALD. Newer pharmaceutical options including GLP-1 receptor agonists (the same drug class as Ozempic and Wegovy) are showing significant benefits in MASLD with metabolic comorbidities, and resmetirom became the first FDA-approved drug specifically for MASH in 2024.

To your health,

Ageless CoachTM

Age Strong. Live Long.

This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reading this article does not create a provider-patient relationship. Always consult your physician or qualified healthcare provider before making changes to your diet, exercise, or health routine. Ageless Coach is not liable for any actions taken based on this information.